3.185

1.10% 0.035

Accolade Inc (ACCD)

Overview News Price History Option Chain Financials Why ACCD Down? Discussions Forecast

Accolade Inc stock is traded at $3.185, with a volume of 402.69K. It is up +1.10% in the last 24 hours and down -15.08% over the past month. Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.

Previous Close:

$3.15

Open:

$3.16

24h Volume:

402.69K

Relative Volume:

0.35

Market Cap:

$259.33M

Revenue:

$414.29M

Net Income/Loss:

$-99.81M

P/E Ratio:

-1.6462

EPS:

-1.9348

Net Cash Flow:

$-28.65M

1W Performance:

-3.50%

1M Performance:

-15.08%

6M Performance:

-57.76%

1Y Performance:

-56.13%

1-Day Range:

$3.10

$3.225

1-Week Range:

$3.08

$3.40

52-Week Range:

$3.08

$15.36

Accolade Inc Stock (ACCD) Company Profile

Name

Accolade Inc

Sector

Healthcare (1181)

Industry

Health Information Services (61)

Phone

610-834-2989

Address

660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING

Employee

2,400

Twitter

Next Earnings Date

2024-07-27

Latest SEC Filings

ACCD's Discussions on Twitter

Accolade Inc Stock (ACCD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-17-24	Resumed	DA Davidson	Neutral
Jan-03-24	Initiated	Barclays	Equal Weight
May-24-23	Upgrade	BofA Securities	Neutral → Buy
Apr-12-23	Initiated	Stephens	Overweight
Mar-23-23	Upgrade	Guggenheim	Neutral → Buy
Feb-09-23	Downgrade	Jefferies	Buy → Hold
Feb-02-23	Initiated	Raymond James	Outperform
Sep-08-22	Resumed	Piper Sandler	Overweight
Sep-07-22	Initiated	Truist	Buy
Aug-12-22	Initiated	DA Davidson	Buy
May-02-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Apr-29-22	Downgrade	BTIG Research	Buy → Neutral
Apr-29-22	Downgrade	BofA Securities	Buy → Neutral
Apr-29-22	Downgrade	Credit Suisse	Outperform → Neutral
Apr-29-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-29-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-11-22	Initiated	Wells Fargo	Underweight
Apr-07-22	Initiated	Guggenheim	Neutral
Apr-01-22	Resumed	Credit Suisse	Outperform
Feb-11-22	Initiated	Goldman	Buy
Dec-02-21	Initiated	Jefferies	Buy
Sep-30-21	Initiated	Berenberg	Buy
Sep-17-21	Upgrade	Robert W. Baird	Neutral → Outperform
May-28-21	Initiated	Robert W. Baird	Neutral
May-06-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Apr-15-21	Initiated	Needham	Buy
Mar-11-21	Resumed	Goldman	Buy
Jan-15-21	Upgrade	Credit Suisse	Neutral → Outperform
Jan-07-21	Initiated	BTIG Research	Buy
Dec-08-20	Initiated	Canaccord Genuity	Buy
Sep-22-20	Initiated	DA Davidson	Buy
Jul-27-20	Initiated	BofA Securities	Buy
Jul-27-20	Initiated	Credit Suisse	Neutral
Jul-27-20	Initiated	Goldman	Buy
Jul-27-20	Initiated	Morgan Stanley	Overweight
Jul-27-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Initiated	Robert W. Baird	Outperform
Jul-27-20	Initiated	SVB Leerink	Outperform

View All

Accolade Inc Stock (ACCD) Latest News

02:11 AM

Vanguard Group Inc's Strategic Acquisition of Accolade Inc Shares - GuruFocus.com

02:11 AM

Nov 04, 2024

Accolade stock hits 52-week low at $3.12 amid market challenges - Investing.com Canada

Nov 04, 2024

Accolade Sports CollectionOfficial Trailer - GameRant

Nov 04, 2024

Nov 01, 2024

Analysts Set Accolade, Inc. (NASDAQ:ACCD) Price Target at $9.04 - MarketBeat

Nov 01, 2024

Oct 31, 2024

QUByte announces Accolade Sports Collection, scrolling brawler Blades & Battles, and a whole lot more - Games Asylum

Oct 31, 2024

Accolade (ACCD) Loses -15.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Oct 26, 2024

Oct 21, 2024

Accolade stock hits 52-week low at $3.35 amid market challenges - Investing.com Australia

Oct 21, 2024

Oct 19, 2024

Accolade CFO Stephen Barnes sells shares worth $447 By Investing.com - Investing.com Australia

Oct 19, 2024

Oct 18, 2024

Accolade CFO Stephen Barnes sells shares worth $447 - Investing.com

Oct 18, 2024

Accolade president Robert Cavanaugh sells shares for $576 - Investing.com

Oct 18, 2024

Accolade president Robert Cavanaugh sells shares for $576 By Investing.com - Investing.com South Africa

Oct 18, 2024

Oct 16, 2024

AcCOLADE CFO Barnes sells shares worth $859 By Investing.com - Investing.com South Africa

Oct 16, 2024

Accolade CEO Rajeev Singh sells $2,564 in stock By Investing.com - Investing.com Australia

Oct 16, 2024

AcCOLADE CFO Barnes sells shares worth $859 - Investing.com India

Oct 16, 2024

Oct 15, 2024

AcCOLADE president Robert Cavanaugh sells shares worth $818 By Investing.com - Investing.com Canada

Oct 15, 2024

AcCOLADE president Robert Cavanaugh sells shares worth $818 - Investing.com India

Oct 15, 2024

Accolade Welcomes Renalogic to Trusted Partner Ecosystem - PR Newswire

Oct 15, 2024

Oct 13, 2024

Rheome earns "Outstanding Performer" accolade from The Arc Jefferson-St. Lawrence - North Country Now

Oct 13, 2024

Oct 12, 2024

Wells Fargo sees potential revenue push for Accolade stock into FY26 amid delayed bookings - Investing.com India

Oct 12, 2024

Oct 11, 2024

Wells Fargo sees potential revenue push for Accolade stock into FY26 amid delayed bookings By Investing.com - Investing.com South Africa

Oct 11, 2024

Wells Fargo & Company Trims Accolade (NASDAQ:ACCD) Target Price to $6.00 - MarketBeat

Oct 11, 2024